Pharsight

Kyprolis generic

Kyprolis is an anti-myeloma drug, manufactured by Onyx Therapeutics, containing the active ingredient carfilzomib. This drug received its first market authorization on July 20, 2012. It currently holds 12 patents.

When will Kyprolis generic be available?

The last patent of Kyprolis is set to expire on February 27, 2033. Given this, the generic version of Kyprolis can be anticipated shortly after this date.

Kyprolis uses

Kyprolis, with its active ingredient carfilzomib, is predominantly used as a treatment for patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. Its efficacy is also proven in patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Kyprolis patent expiration

Kyprolis holds 12 active patents. The expiration dates of these patents range from April 14, 2025, to February 27, 2033. This suggests that Kyprolis generic will be available post the latter date. Below are the details of the patents:

Kyprolis dosage

Want to ask something?